Boston Scientific Corp

BSX

92.330USD

-1.460-1.56%

Close 01/29, 16:00（ET）Quotes delayed by 15 min

Boston Scientific Corp's Score

Industry at a Glance

Industry Ranking

5 / 205

Overall Ranking

60 / 4540

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Boston Scientific Corp Highlights

StrengthsRisks

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.05% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 16.75B.

Undervalued

The company’s latest PE is 48.91, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.40B shares, decreasing 0.03% quarter-over-quarter.

Held by Mairs and Power

Star Investor Mairs and Power holds 26.18K shares of this stock.

Analyst Rating

Based on 36 analysts

Buy

Current Rating

123.396

Target Price

+31.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Boston Scientific Corp is 8.86, ranking 27 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 5.07B, representing a year-over-year increase of 20.34%, while its net profit experienced a year-over-year increase of 60.98%.

Score

Industry at a Glance

Previous score

8.86

Change

0



Financials

7.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.08

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.72

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Boston Scientific Corp is 5.88, ranking 178 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 48.91, which is 125.98% below the recent high of 110.52 and 4.61% above the recent low of 46.65.

Score

Industry at a Glance

Previous score

5.88

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 5/205

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Boston Scientific Corp is 8.67, ranking 16 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 127.00, with a high of 140.00 and a low of 101.45.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Boston Scientific Corp is 7.36, ranking 50 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 99.81 and the support level at 85.94, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.52

Change

-0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-01-29

The current institutional shareholding score of Boston Scientific Corp is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 94.34%, representing a quarter-over-quarter decrease of 0.24%. The largest institutional shareholder is The Vanguard, holding a total of 137.57M shares, representing 9.28% of shares outstanding, with 2.46% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

137.57M

+0.80%

Fidelity Management & Research Company LLC

90.62M

-8.90%

BlackRock Institutional Trust Company, N.A.

79.60M

+1.81%

State Street Investment Management (US)

64.93M

-0.41%

PRIMECAP Management Company

Star Investors

33.10M

-4.50%

Geode Capital Management, L.L.C.

32.69M

+0.82%

Capital World Investors

26.65M

-6.58%

Managed Account Advisors LLC

23.16M

+5.03%

The Bollard Group, LLC

19.73M

-1.72%

Norges Bank Investment Management (NBIM)

19.46M

-1.39%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Boston Scientific Corp is 9.44, ranking 9 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.67. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Boston Scientific Corp

BSX

8.25 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alcon AG

ALC

8.25 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Glaukos Corp

GKOS

8.22 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment